Long-Term Outcomes With Tarlatamab in Previously Treated SCLC
Updated data from the DeLLphi-300 study suggest that tarlatamab can produce durable responses in patients with previously treated SCLC.
Updated data from the DeLLphi-300 study suggest that tarlatamab can produce durable responses in patients with previously treated SCLC.
Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.
David Y.T. Chen, MD, has been recognized as a 2024 Castle Connolly Top Doctor and named to Castle Connolly’s Top AAPI Doctors list.
In his closing remarks, Yi-Bin Chen, MD, shares his aspirations for the future of graft versus host disease management, emphasizing the need for further clinical…
High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.
Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.
Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE…
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
GeekWire co-founders Todd Bishop, left, and John Cook open the 2024 GeekWire Awards at Showbox SoDo in Seattle on Thursday. (GeekWire Photo / Kevin
Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.
Event in Whiteville, TN by Elizabeth Young on Friday, June 7 2024